Goserelin-d7

Goserelin-d7 (ICI 118630-d7) is deuterium labeled Goserelin. Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer[1][2].

Product Specifications

Product Name Alternative

ICI 118630-d7

UNSPSC

12352005

Target

Apoptosis; GnRH Receptor; Isotope-Labeled Compounds

Related Pathways

Apoptosis; GPCR/G Protein; Others

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Cancer; Endocrinology

Smiles

O=C([C@@H]1CCC(N1)=O)N[C@@H](CC2=CN=CN2)C(N[C@H](C(N[C@@H](CO)C(N[C@H](C(N[C@H](COC(C)(C)C)C(N[C@@H](CC(C([2H])([2H])[2H])([2H])C([2H])([2H])[2H])C(N[C@@H](CCCNC(N)=N)C(N3[C@@H](CCC3)C(NNC(N)=O)=O)=O)=O)=O)=O)CC4=CC=C(C=C4)O)=O)=O)CC5=CNC6=CC=CC=C56)=O

Molecular Formula

C59H77D7N18O14

Molecular Weight

1276.45

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Ning Zhang, et al. Goserelin promotes the apoptosis of epithelial ovarian cancer cells by upregulating forkhead box O1 through the PI3K/AKT signaling pathway. Oncol Rep. 2018 Mar; 39 (3) : 1034–1042.|[3]Halle C F Moore, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015 Mar 5;372 (10) :923-32.